© The Author(s) Published by Science and Education Publishing.

Slides:

Advertisements

Similar presentations

Anbazhagan R. Classification of Small Cell Lung Cancer and Pulmonary Carcinoid by Gene Expression Profiles. Cancer research. 1999; 59:5119 –5122.

Advertisements

台北榮民總醫院婦產部主治醫師吳華席. Introduction Ovarian cancer –The lethal gynecologic cancer The major prognostic factors –Residual tumor at primary surgery –Sensitivity.

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.

CALYPSO Trial: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum- Sensitive Ovarian Cancer Pujade-Lauraine.

Relapsed/Refractory Ovarian Cancer: Decision Points in Diagnosis and New Treatment Strategies Friday, March 24, 2006 Palm Springs Convention Center Primrose.

and Statistics, 2016, Vol. 4, No. 1, 1-8. doi: /ajams-4-1-1

Table 3. Awareness of MAUTech students on cancer biotherapy

© The Author(s) Published by Science and Education Publishing.

Table 1. Empirical MSE to estimate the CP distribution parameter λ

Number of brain metastasis

Nicoletta Colombo, Martin Gore

Figure 5. Hepatoprotective effects of propolis against DOX-induced toxic effects. Photomicrograph of rats’ liver section of group III (Propolis-DOX treated.

PHASE I/II STUDY OF PEGYLATED LIPOSOMAL DOXORUCIN (PLD) AND GEMCITABINE (GEM) IN RECURRENT PLATIN RESISTANT OVARIAN CANCER (OC). A Study of the VWOG.

Research, 2015, Vol. 3, No. 6, doi: /education

Table 1. The French-American-British (FAB) classification of AML

SON Nurse Practitioner Blackboard Community

© The Author(s) Published by Science and Education Publishing.

Tensile Test after Firing

Caris Molecular Intelligence®

© The Author(s) Published by Science and Education Publishing.

Titratable acidity (g/100g)

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Source Sum of Squares (SS) df Mean Square (MS) F p-value

Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

PARP Inhibitors and Cancer: What Do You Need to Know?

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Management Philosophy

PARP Inhibitors and Ovarian Cancer: What Did Data From Washington, DC, Tell Us?

© The Author(s) Published by Science and Education Publishing.

Maintenance Therapy in Advanced Ovarian Cancer

PARP Inhibitors.

Table 1. Descriptive data of movement form scores

Molecular Testing in Ovarian Cancer: Is the Time Now?

Scott A. Elman, James H. Ware, Alice B. Gottlieb, Joseph F. Merola

Table 6. Control sample industry distribution

Table 1. The radial spheroidal functions

Year range Rainfall (mm) ∆s in rainfall Temp (°C) ∆s in temp RH (mm)

© The Author(s) Published by Science and Education Publishing.

© The Author(s) Published by Science and Education Publishing.

Rating of Water Quality

© The Author(s) Published by Science and Education Publishing.

© The Author(s) Published by Science and Education Publishing.

© The Author(s) Published by Science and Education Publishing.

Number of categories that are mentioned (0% < categories < 5%)

Table 1. Diagnostic methods for systemic fungal infection (n=70)

Table 2. Modal parameters estimated by Pulse Reflex®

Entrapment Efficiency (%) ± S.D.

Number of questionnaires sent out

© The Author(s) Published by Science and Education Publishing.

© The Author(s) Published by Science and Education Publishing.

Table 1. Histological disease score

Table 1. Descriptive Statistics

© The Author(s) Published by Science and Education Publishing.

© The Author(s) Published by Science and Education Publishing.

Table 2. SUMMARIZED OBSERVATIONS FROM MODEL ANALYSIS

Table 1. Measurements of LEDs

Cumulative Percentage

Cumulative Percentage

Table 3. Correlation of PC, MC, RC & IC at the Supervisory level

Selected overview of clinical trials evaluating FGFR signaling–targeted therapies currently under development (monotherapy). Selected overview of clinical.

Category Quantity Secondary school 3 Student participant

Table 4. Value creation (Y2)

Table 7. The Result of T Test After Treatment

Compressive Strength difference at 1 week (MPa)

Table 6. Twisting moment of counter shaft at different torques

© The Author(s) Published by Science and Education Publishing.

Average Execution Time in seconds

© The Author(s) Published by Science and Education Publishing.

Education, 2016, Vol. 4, No. 1, doi: /wjce-4-1-4

Presentation transcript:

© The Author(s) 2015. Published by Science and Education Publishing. Table 1. Selected open phase II/III trials in platinum resistant ovarian cancer Trial No Protocol Type NCT02580058 Avelumab with or with out Pegylated Liposomal doxorubicin Phase III NCT 02421588 (COPAIL) Lurbinectedin Vs PLD or topotecan NCT 02502266 Cediranib & olaparib Vs Chemotherapy Phase II/III NCT 02354586 Niraparib (single arm) Phase II NCT 02608684 Pembrolizumab with cisplatin & gemicitabine NCT 02272790 AZD1775 with or without combination chemotherapy EORTC 55092 Pazopanib in combination with carboplatin/taxol S.G.D. Ganghadaran et al. Management of Platinum Resistant – Refractory Ovarian Cancer: A Short Review. Journal of Cancer Research and Treatment, 2016, Vol. 4, No. 2, 32-36. doi:10.12691/jcrt-4-2-3 © The Author(s) 2015. Published by Science and Education Publishing.